Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients
about
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeAnticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decadeRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsGastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentSubdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literatureDual pathway therapy in acute coronary syndrome.Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation.Anticoagulation after anterior myocardial infarction and the risk of stroke.Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature.Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.Antithrombotic therapy in patients with acute coronary syndrome in the intermountain heart collaborative studyAntithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in miceA Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease.Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation.Inappropriate preinjury warfarin use in trauma patients: A call for a safety initiative.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.The role of apixaban for venous and arterial thromboembolic disease.New anticoagulants in ischemic heart disease.Rivaroxaban for the treatment of acute coronary syndromes.Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.New antithrombotics for secondary prevention of acute coronary syndrome.Rivaroxaban: a review of its use in acute coronary syndromes.Rivaroxaban in acute coronary syndromes--is it prime time?Recent advances in antithrombotic treatment for acute coronary syndromes.The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention.Rivaroxaban for the treatment and prevention of thromboembolic disease.Investigational new drugs for the treatment of acute coronary syndrome.Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis.Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction.
P2860
Q22242896-267CC04F-B493-4A37-977C-E041121308A1Q24623137-979A2052-2C5B-4CDD-B767-46901813997EQ26824864-383950E4-8319-413A-8CA7-1094B8960178Q26825230-CC03A4E1-F6F5-4C8F-A935-6267B95FC773Q26828817-70CCB12A-E443-4C67-804F-15B0C8544382Q27027977-615EFB13-3222-433E-88A7-6A10E69859B4Q28213487-E1F220C9-1E54-4123-A344-19E91280AD1FQ30252011-2BA0253F-4012-48E7-AC4C-C32AE38302B8Q30680968-B9E80F56-6125-4444-9B2A-9837A21DF913Q33632559-8438328B-2B99-454E-97C5-A12A8ED2B845Q33668758-6B1AEB47-C2D5-418D-9F61-0D52559ABF87Q33721188-CF40F27E-A358-424F-928D-56A1B6ACF5DBQ33936118-24BAD601-1ED8-4CCD-92CB-8D0A294C59FAQ34252907-437B6D6A-6797-443E-9541-990C8BA195CCQ34364050-D965027F-8551-41D6-84A8-4D084313C117Q34997324-771083CB-EF91-45A0-ACA7-703F4F070ECFQ35111496-9B6343DE-92AA-4EFD-9294-51C8579FA752Q36110533-146FA087-D515-44D6-A0BD-6EBC89D50DC6Q36194774-9CA7F709-8CBF-4BC6-B881-7F112236E038Q36496846-37011E14-3467-485D-A18F-A076E5B59831Q37093625-E32110E5-7F8E-4FCF-8880-5739B65CE7EBQ37251490-16F470A8-647B-4FC3-ABBE-D1467ECB9FF0Q37536810-3A0B1008-F36E-48A9-815E-03CF95C3DD69Q37827882-36672F08-80C6-4FB9-B32F-3955D5F6CE92Q37939851-CD27D19D-D47A-4DE3-8387-439C87BD732AQ38005012-0E8615CB-1655-4EAC-99EB-3DB45C217745Q38094797-A20D5516-0B6E-4D79-A75D-E631D29F5707Q38130753-1BEFFFA0-9B61-4BC8-9382-CCBCDC82B2CEQ38171396-F4935456-AB27-4A4E-B4F5-3C0EBB6BDD60Q38180991-2E91CDC4-23B8-4D03-92D4-F252BF7EAA67Q38188899-F1B04F9B-E481-49B9-94F6-D2F912343D47Q38205559-25F25F3F-10DA-4C01-B6A0-D0C024E0490AQ38216600-9E854276-E7AB-458A-BCDF-2252883D51F4Q38217362-852D1169-986C-4DEA-AD9E-3B1300DBE1F6Q38398587-1354A798-09C6-421D-BFC8-2D375D713302Q38522824-D200F435-C66B-4965-B92A-089C0C328B6DQ38594609-50F8F607-2535-4475-A333-50EFBDE7CAD1Q38992107-C460206A-BB2C-46BF-93F0-90E95C38C230Q39031152-9E9FDAE9-E9A5-4D79-A41A-AAC44CD900CDQ41532376-1635EB8E-A0BD-4A20-AF95-7DA770930974
P2860
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients
description
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im März 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: March 2006)
@en
vedecký článok (publikovaný 2006-03)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd in 2006-03)
@nl
наукова стаття, опублікована в березні 2006
@uk
مقالة علمية (نشرت في مارس 2006)
@ar
name
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@ast
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@en
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@nl
type
label
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@ast
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@en
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@nl
prefLabel
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@ast
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@en
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@nl
P2093
P921
P356
P1476
Aspirin plus warfarin compared ...... ta-analysis of 25,307 patients
@en
P2093
Felicita Andreotti
Filippo Crea
Giuseppe G L Biondi-Zoccai
Luca Testa
P304
P356
10.1093/EURHEARTJ/EHI485
P407
P577
2006-03-01T00:00:00Z